Santhera and ReveraGen Announce New 2 . 5 - year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy

Two leading drugs have announced new clinical data for patients with Duchenne muscular dystrophy (DMD) which show a maintenance of treatment effect, equivalent to two years in decline for time to stand (TTstand). Scientists say they believe the drug s safety and tolerability benefits are significant.

Published on 2021-04-29